Gleevec
Trovati 27 articoli
- Systemic mastocytosis responds to Imatinib
- A rare disorder caused by an excess of two types of immune cells, the mast cell found in various tissues and its blood-based twin, the basophil, has successfully been treated with a cancer drug, report scientists from the NIAID ( National Institute of Allergy and Infectious Diseases ), part of th... (Leggi Articolo)
- Imatinib during pregnancy may cause fetal abnormalities
- Treating pregnant women with leukaemia can be quite difficult as studies suggest that certain therapies can harm developing fetuses. According to the results of a study prepublished in the Blood, the journal of the American Society of Hematology, expectant women treated with Imatinib ( Gleevec, G... (Leggi Articolo)
- Metastatic melanoma with KIT mutations responds to Imatinib
- Researchers at Dana-Farber Cancer Institute have reported the first instance in which metastatic melanoma has been driven into remission by a targeted therapy. The report, published in the Journal of Clinical Oncology, describes the case of a 79-year-old woman with melanoma tumors in several par... (Leggi Articolo)
- Imatinib appears effective in a patient with systemic mastocytosis
- A rare disorder caused by an excess of two types of immune cells, the mast cell found in various tissues and its blood-based twin, the basophil, has successfully been treated with a cancer drug, report researchers from the National Institute of Allergy and Infectious Diseases ( NIAID ), part of t... (Leggi Articolo)
- Imatinib and Sunitinib prevent, reverse type 1 diabetes in murine model
- Two anticancers have shown prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco ( UCSF ). The drugs, Imatinib ( Gleevec, Glivec ) and Sunitinib ( Sutent ), were found to put type 1 diabetes into remis... (Leggi Articolo)
- Chronic myelogenous leukaemia: activation of LYN kinase is associated with resistance to Glivec
- Activation of LYN kinase is associated with resistance to Imatinib ( Gleevec, Glivec ) in patients with chronic myelogenous leukemia ( CML ). Imatinib is the standard therapy for newly diagnosed CML patients. However, some patients develop resistance to the drug over time. In some patients, re... (Leggi Articolo)
- Primary gastrointestinal stromal tumor: Imatinib decreases cancer recurrence
- Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor ( GIST ), a type of tumor usually found in the stomach or small intestine, showed that patients who received Imatinib ( Glivec / Gleevec ) after complete remova... (Leggi Articolo)
- Tasigna in treatment of Ph+ chronic myeloid leukaemia, FDA approved
- The FDA ( Food and Drug Administration ) has approved Tasigna ( Nilotinib ) capsules for treatment of Philadelphia chromosome positive chronic myeloid leukemia ( CML ) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included Imatinib. Imatinib ( G... (Leggi Articolo)
- Gleevec proves safe and effective over the long term in chronic myeloid leukemia
- The drug Imatinib mesylate, more commonly known as Gleevec ( Europe: Glivec ), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia ( CML ). A team of researchers followed 454 patients with chronic-phase chronic myeloid leukemia taking Imat... (Leggi Articolo)
- Sprycel circumvents Glivec resistance in chronic myeloid leukemia
- Dasatinib ( Sprycel ) reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Imatinib ( Gleevec / Glivec ), which is considered the standard of treatment for the disorder. In a study published in The New England Journal of Medicine ( NEJM ), Howard... (Leggi Articolo)
- High overall survival after five years on Imatinib in chronic myelogenous leukemia
- A study of the Oregon Health & Science University ( OHSU ) Cancer Institute has shown that the overall survival of most people with chronic myelogenous leukemia ( CML ) treated with Imatinib ( Gleevec / Glivec, STI-571 ) is extremely high and the relapse rate is quite low. The overall surviva... (Leggi Articolo)
- Gleevec attacks prostate cancer in mouse model by destroying its blood supply
- Researchers from The University of Texas M. D. Anderson Cancer Center reported in the Journal of the National Cancer Institute ( JNCI ) that Imatinib, a medication used to treat other types of cancer, strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply. Imati... (Leggi Articolo)
- Five-year study shows Glivec's excellent survival rate
- A 5-year follow-up of patients with chronic myeloid leukemia ( CML ) who began continuous treatment with Imatinib ( Glivec / Gleevec ) reports that the drug can induce durable hematologic and cytogenetic responses in a high proportion of patients. When the drug first was developed by Brian J D... (Leggi Articolo)
- Tasigna when Glivec fails in chronic myelogenous leukaemia
- Nilotinib ( AMN107, Tasigna ) appears to offer striking benefits in patients with chronic myelogenous leukemia ( CML ) who are resistant to Imatinib ( Gleevec / Glivec ), the standard therapy for this cancer, according to researchers at The University of Texas M. D. Anderson Cancer Center. Re... (Leggi Articolo)
- FDA has approved Sutent in GIST and advanced kidney cancer
- The FDA ( Food and Drug Administration ) announced approval of Sutent ( Sunitinib ), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors ( GIST ), a rare stomach cancer, and advanced kidney cancer. Sutent is a tyrosine kinase inhibitor working through multip... (Leggi Articolo)
- CDK4 as a targeted approach to treating aggressive breast cancers
- Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment. A team led by Qunyan Yu, and Peter Sicinski, of Dana-Farber r... (Leggi Articolo)
- Sutent shows promise in children with metastatic GIST resistant to Imatinib
- A small pilot study from researchers at Dana-Farber Cancer Institute has shown that children with a rare digestive-tract cancer that is resistant to front-line therapy may benefit from a newer targeted therapy that has been shown effective in adults. Researchers led by Katherine Janeway, and ... (Leggi Articolo)
- Sprycel in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia, FDA approved
- The FDA ( Food and Drug Administration ) has approved Sprycel ( Dasatinib ), an oral inhibitor of multiple tyrosine kinases, for the treatment of adults in all phases of chronic myeloid leukemia ( CML ) ( chronic, accelerated, or myeloid or lymphoid blast phase ) with resistance or intolerance t... (Leggi Articolo)
- Europe: Sprycel for treatment-resistant chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia
- The European Commission approved Sprycel ( Dasatinib ) for the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy, including Imatinib ( Glivec / Gleevec ). Sprycel is also indicated for the treatment of adults ... (Leggi Articolo)
- Basic research at the Max Planck Institute of Biochemistry leads to a novel cancer therapy
- Axel Ullrich, at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth, and shrinks its tissue. This fundamental principle led to the development of Sutent ( Sunit... (Leggi Articolo)
- Novartis, new products portfolio
- Novartis has a comprehensive portfolio of cardiovascular products both in the market ( Diovan and Lotrel ) as well as in development ( such as LAF237 and SPP100 ), for the treatment of hypertension, dyslipidemia and diabetes. Other compounds in development include APP018 ( D-4F ), an oral Apo ... (Leggi Articolo)
- Imatinib-resistant leukemia: AMN107 offers benefits in some forms
- Researchers at The University of Texas M. D. Anderson Cancer Center found that AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Imatinib ( Gleevec/Glivec). At the 47th Annual Meeting of the American Society of Hematology ( ASH ), the investigat... (Leggi Articolo)
- Imatinib-resistant GIST: Sutent extends overall survival
- An investigational new drug Sutent ( Sunitinib ) more than doubled survival and significantly reduced tumor growth and spread in patients with Imatinib-resistant gastrointestinal stromal tumors ( GIST ). Encouraging Phase II results also were observed in other tumor types, including metastati... (Leggi Articolo)
- Forskolin may be effective in Imatinib-resistant patients in chronic myelogenous leukaemia
- Researchers have identified a new pathway in the progression of chronic myelogenous leukemia ( CML ). They also discovered that an extract from the root of a common ornamental plant can suppress the process. The findings, appearing in the journal Cancer Cell, may yield new treatment options f... (Leggi Articolo)
- Imatinib slows poxvirus in murine model
- Mice given Imatinib can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases ( NIAID ), part of the National Institutes of Health. The findings, say the investigators, suggest... (Leggi Articolo)
- Chronic myeloid leukemia: advances in therapy
- The results from five studies highlighting new advances in the treatment of chronic myeloid leukemia ( CML ) – a slow-progressing, malignant bone marrow cancer – have been presented at the 47th Annual Meeting of the American Society of Hematology. " The survival rate for leukemia has improved... (Leggi Articolo)
- High grade renal cell carcinoma: Imatinib does not appear to be effective
- Researchers at the Mayo Clinic Cancer Center report that Imatinib ( Gleevec/Glivec ), the drug used to treat patients with gastrointestinal stromal cancers ( GISTs ), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer. Results ... (Leggi Articolo)
